State coverage
California Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Coverage for weight loss ended January 1, 2026. GLP-1s stay covered for other approved uses.
- Appeal deadline
- 90 days from the Notice of Action (start a hearing within 10 days to keep receiving the drug while it's decided) source
- Date read
- August 2026
California stopped paying for GLP-1 drugs used for weight loss on January 1, 2026. The change came out of the 2025-26 state budget, and the state gave a long warning: a countdown alert in October, a second notice three weeks later, a letter mailed to members, and an expiry date on every prior authorization already granted.
That is not the same as the drugs leaving Medi-Cal. The state kept covering them for other uses the FDA has approved, and it still pays for two of the newer weight-management products for narrow reasons that are not weight loss. What ended is weight loss as a reason for Medi-Cal to pay.
One thing makes California simpler to read than most states: the pharmacy benefit runs statewide through Medi-Cal Rx rather than through whichever managed care plan you belong to, and the state's own member letter says the change applies to every Medi-Cal member. Elsewhere on this site you will see us warn that a state posture may not describe your plan. Here, the state said it does.
What we could verify for California
Medi-Cal Rx's provider manual lists GLP-1 drugs used for chronic weight management as an item it does not cover. The manual's words are "Glucagon-like peptide-1 (GLP-1) drugs used for chronic weight management or weight loss-related indications," with an exception "when GLP-1 drugs are used for other FDA-approved indications or for considerations under the EPSDT benefit."
California Department of Health Care Services, Medi-Cal Rx, effective August 2026 · source
Zepbound and Saxenda came off the Contract Drugs List on January 1, 2026 and claims for them now deny regardless of what they were prescribed for. Wegovy stopped being eligible for weight loss on the same date. The state will still consider Zepbound for obstructive sleep apnea, and since April 1, 2026 Wegovy needs no prior authorization at all when it is prescribed for MASH.
California Department of Health Care Services, Medi-Cal Rx, effective April 2026 · source
Seven other GLP-1 drugs — Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity — are still on the Contract Drugs List, still carry a type 2 diabetes diagnosis restriction, and stopped being eligible for weight loss on January 1, 2026. There is one exception the state names: for members younger than 21, a request for a weight-loss indication is still reviewed for medical necessity under the federal EPSDT benefit.
California Department of Health Care Services, Medi-Cal Rx, effective April 2026 · source
The bulletin that announced it is dated October 21, 2025 and names the three drugs dropped for weight loss: Saxenda, Wegovy and Zepbound. It also tells you what a pharmacy sees at the counter — Reject Code 70, Product/Service Not Covered — and that every prior authorization already approved for those drugs expired on December 31, 2025. The document now carries an ARCHIVED watermark, which is what happens to an announcement after its date passes; the policy it announced is the one in force.
California Department of Health Care Services, Medi-Cal Rx, effective January 2026 · source
The letter California mailed to members carries the appeal route. It says members generally have 90 days from the date of the Notice of Action to ask the Department of Social Services in writing for a State Hearing. It also says something easy to miss: a member already taking a GLP-1 who asks for a State Hearing within 10 days of that notice may keep receiving the drug while the hearing is decided.
California Department of Health Care Services, Medi-Cal Rx, effective November 2025 · source
The same letter settles the question of who this applies to, in four words: "This change is for all Medi-Cal members." California administers the pharmacy benefit statewide through Medi-Cal Rx, so unlike most states there is no separate managed care drug list that could answer differently.
California Department of Health Care Services, Medi-Cal Rx, effective November 2025 · source
California is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. California Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare California with the rest in the coverage matrix.
Regional insurers that sell plans in California and have their own page here, quoted from their own policy documents: Kaiser Permanente California. The national insurers are on the insurance index.
If you work for the State of California
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: CalPERS health plans. Its pharmacy benefit runs through CVS Caremark for the self-insured plans; the Kaiser and Blue Shield HMOs run their own.
Weight loss excluded, except BMI 40+ in two HMOs
CalPERS doesn't cover GLP-1s for weight loss in its self-insured plans. Its Kaiser Permanente and Blue Shield HMOs cover them at a BMI of 40 or more with prior authorization, and every plan still covers them for diabetes and some related conditions.
"CalPERS' Knox-Keene regulated plans that manage their own pharmacy benefit, including HMO plans offered by Blue Shield of California and Kaiser Permanente, cover GLP-1 medications for morbid obesity (BMI ≥ 40 kg/m2), subject to prior authorization requirements."
CalPERS Board of Administration, Agenda Item 8c, Senate Bill 1089 (Richardson), effective June 2026 · source
"CalPERS' self-insured pharmacy benefit manager covers non-GLP-1 anti-obesity medications for the treatment of overweight and obesity, including Phentermine, Qsymia and Contrave."
CalPERS Board of Administration, Agenda Item 8c, Senate Bill 1089 (Richardson), effective June 2026 · source
"All CalPERS health plans currently cover GLP-1 medications for diabetes and certain obesity-related conditions, including obstructive sleep apnea, cardiovascular risk factors, and Metabolic Dysfunction-Associated Steatohepatitis. Coverage varies by health plan and clinical indication."
CalPERS Board of Administration, Agenda Item 8c, Senate Bill 1089 (Richardson), effective June 2026 · source
Staff recommended opposing a bill that would require coverage: "Adopt an OPPOSE position on Senate Bill (SB) 1089 (Richardson), as amended May 14, 2026. SB 1089 would require California Public Employees' Retirement System (CalPERS) health plans to cover at least one GLP-1 medication for the treatment of overweight and obesity."
CalPERS Board of Administration, Agenda Item 8c, Senate Bill 1089 (Richardson), effective June 2026 · source
If the appeal fails, or you cannot wait
California Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerShedRxCheck availability | Injections plus needle-free drops and lozenges. You see a price only after the questionnaire, and the oral forms aren't sold in sixteen states. |
| PartnerHealthRXCheck availability | Compounded semaglutide at $133 a month on a three-month plan ($99 on twelve), tirzepatide from $209 ($179 on twelve). Its member reviews are labeled illustrative composites, not real patients. |
| PartnerMEDGmCheck availability | GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery. |
| PartnerBodybuilding Health+Check availability | Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC. |
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- California Department of Health Care Services, Medi-Cal Rx, effective August 2026 — medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/fo
- California Department of Health Care Services, Medi-Cal Rx, effective April 2026 — medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/20
- California Department of Health Care Services, Medi-Cal Rx, effective January 2026 — medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/pu
- California Department of Health Care Services, Medi-Cal Rx, effective November 2025 — www.medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/